Option chain shows key data for Ayala Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ayala Pharmaceuticals.

Ayala Pharmaceuticals (OTC:ADXS) Stock, Option Chain

Advaxis

AYALA PHARMACEUTICALS INC by Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals

Overview

News

Earnings

Analyst Ratings

Insider Trades

Short Interest

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.

Comments

Ayala Pharmaceuticals Option Chain

No option chain data available. Please try again later